HUP0400316A2 - CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents
CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0400316A2 HUP0400316A2 HU0400316A HUP0400316A HUP0400316A2 HU P0400316 A2 HUP0400316 A2 HU P0400316A2 HU 0400316 A HU0400316 A HU 0400316A HU P0400316 A HUP0400316 A HU P0400316A HU P0400316 A2 HUP0400316 A2 HU P0400316A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- mono
- alkyl
- compounds
- cycloalkyl
- Prior art date
Links
- 101150105710 CRF1 gene Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000005432 dialkylcarboxamide group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010048327 Supranuclear palsy Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- -1 nitro- Chemical class 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
A találmány tárgya (I) általános képletű 5-szubsztituált-2-arilpiridin-származékokra, a vegyületeket tartalmazógyógyszerkészítményekre, valamint e vegyületek alkalmazására isvonatkozik, pszichiátriai betegségek, valamint neurológiai betegségek,így súlyos depresszió, szorongás, poszttraumatikus stressz,szupranukleáris bénulás és táplálkozási rendellenességek kezelésénél,valamint immunológiai, szív és érrendszeri betegségek, érzékenyvastagbél szindróma és pszichopatológiai zavarok és stressz miattbekövetkező vastagbél-túlérzékenység kezelésénél. Az (I) általánosképletű vegyületek vagy gyógyászatilag elfogadható sója, ahol Arjelentése fenil-, 1-naftil-, 2-naftil-csoport, amelyek bármelyikeegy-, két- vagy három helyen lehet szubsztituálva, továbbá Arjelentése 1-3 gyűrűt tartalmazó, mono-, di- vagy triszubsztituáltheteroarilcsoport, ahol mindegyik gyűrű 5-7 tagú és legalább egy gyűrű1-3 heteroatomot tartalmaz. R jelentése oxigénatom vagy hiányzik. R2jelentése adott esetben szubsztituált alkil-, adott esetbenszubsztituált alkenil-, adott esetben szubsztituált alkinil-, adottesetben szubsztituált alkoxi-, adott esetben szubsztituált mono- vagydialkil-amino-, adott esetben szubsztituált alkil-tio-, adott esetbenszubsztituált alkilszulfinil-, adott esetben szubsztituált alkil-szulfonil-, adott esetben szubsztituált mono- vagy dialkil-karboxamid-, adott esetben szubsztituált aril- vagy adott esetbenszubsztituált heteroarilcsoport, ahol a heteroarilcsoport 1-3 gyűrűttartalmaz, mindegyik gyűrű 5-7 tagú és legalább egy gyűrű 1-3heteroatomot tartalmaz. R1, R3 és R4 jelentése egymástól függetlenülhidrogénatom, halogénatom, nitro-, adott esetben szubsztituált alkil-,adott esetben szubsztituált alkenil-, adott esetben szubsztituáltalkinil-, adott esetben szubsztituált alkoxi-, adott esetbenszubsztituált mono- vagy dialkil-amino-, adott esetben szubsztituáltcikloalkil-, adott esetben szubsztituált cikloalkil-alkil-, adottesetben szubsztituált cikloaklil-oxi-, adott esetben szubsztituáltcikloalkil-alkoxi-, adott esetben szubsztituált alkil-tio-, adottesetben szubsztituált alkilszulfinil-, adott esetben szubsztituáltalkil-szulfonil- vagy adott esetben szubsztituált mono- vagy dialkil-karboxamid-csoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29270301P | 2001-05-22 | 2001-05-22 | |
| PCT/US2002/016529 WO2002096421A1 (en) | 2001-05-22 | 2002-05-22 | 5-substituted-2-arylpyridines as crf1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0400316A2 true HUP0400316A2 (hu) | 2005-02-28 |
Family
ID=23125823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400316A HUP0400316A2 (hu) | 2001-05-22 | 2002-05-22 | CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7223778B2 (hu) |
| EP (1) | EP1392302A1 (hu) |
| JP (1) | JP2004531570A (hu) |
| KR (1) | KR20040015716A (hu) |
| AP (1) | AP2003002920A0 (hu) |
| BG (1) | BG108490A (hu) |
| BR (1) | BR0209920A (hu) |
| CA (1) | CA2448198A1 (hu) |
| EC (1) | ECSP034860A (hu) |
| HR (1) | HRP20031056A2 (hu) |
| HU (1) | HUP0400316A2 (hu) |
| IL (1) | IL158958A0 (hu) |
| IS (1) | IS7046A (hu) |
| MX (1) | MXPA03010692A (hu) |
| NO (1) | NO20035183D0 (hu) |
| PL (1) | PL367153A1 (hu) |
| RU (1) | RU2003134010A (hu) |
| SK (1) | SK15432003A3 (hu) |
| TN (1) | TNSN03119A1 (hu) |
| WO (1) | WO2002096421A1 (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| WO2004043925A2 (en) * | 2002-11-08 | 2004-05-27 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| WO2005007627A1 (ja) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤 |
| US20070099938A1 (en) * | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
| EP3696174A1 (en) | 2005-11-08 | 2020-08-19 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| CN101687842B (zh) | 2007-05-09 | 2013-03-06 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| CN101790517B (zh) * | 2007-08-01 | 2013-08-21 | 大正制药株式会社 | 抑制s1p1结合的物质 |
| LT2639223T (lt) * | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
| AU2013205160B2 (en) * | 2007-12-07 | 2016-05-19 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
| WO2011127241A2 (en) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| JP6219922B2 (ja) * | 2012-03-30 | 2017-10-25 | ダウ アグロサイエンシィズ エルエルシー | ３−置換−６−トリフルオロメチルピリジンを調製する方法およびハロゲン化６−トリクロロメチルピリジンを使用する方法 |
| KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
| CN107110831B (zh) | 2014-11-18 | 2020-02-21 | 弗特克斯药品有限公司 | 进行高通量试验高效液相色谱的方法 |
| KR101750453B1 (ko) | 2015-09-11 | 2017-06-23 | 동아대학교 산학협력단 | 손잡이 세정이 가능한 샤워헤드용 방향제어밸브 |
| US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1147068A (en) * | 1966-12-02 | 1969-04-02 | Ici Ltd | Phenyl-pyridine derivatives |
| GB9012017D0 (en) * | 1990-05-30 | 1990-07-18 | Ici Plc | Fungicidal compounds |
| DE4315867A1 (de) * | 1993-05-12 | 1994-11-17 | Hoechst Ag | 3-Chlorpyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Flüssigkristallmischungen |
| DE4323916A1 (de) * | 1993-07-16 | 1995-01-19 | Basf Ag | Substituierte 2-Phenylpyridine |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5849758A (en) * | 1995-05-30 | 1998-12-15 | American Cyanamid Company | Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines |
| DE19748439A1 (de) * | 1997-11-03 | 1999-05-06 | Hoechst Ag | 1,6-Disubstituierte Naphthalinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
| EA006938B1 (ru) * | 2000-02-16 | 2006-06-30 | Ньюроджин Корпорейшн | Замещенные арилпиразины |
| WO2001068614A2 (en) | 2000-03-16 | 2001-09-20 | Neurogen Corporation | 5-substituted arylpyrimidines |
-
2002
- 2002-05-22 EP EP02741732A patent/EP1392302A1/en not_active Withdrawn
- 2002-05-22 KR KR10-2003-7015197A patent/KR20040015716A/ko not_active Application Discontinuation
- 2002-05-22 CA CA002448198A patent/CA2448198A1/en not_active Abandoned
- 2002-05-22 US US10/154,396 patent/US7223778B2/en not_active Expired - Fee Related
- 2002-05-22 SK SK1543-2003A patent/SK15432003A3/sk unknown
- 2002-05-22 MX MXPA03010692A patent/MXPA03010692A/es unknown
- 2002-05-22 AP APAP/P/2003/002920A patent/AP2003002920A0/en unknown
- 2002-05-22 HU HU0400316A patent/HUP0400316A2/hu unknown
- 2002-05-22 IL IL15895802A patent/IL158958A0/xx unknown
- 2002-05-22 BR BR0209920-9A patent/BR0209920A/pt not_active Application Discontinuation
- 2002-05-22 WO PCT/US2002/016529 patent/WO2002096421A1/en not_active Application Discontinuation
- 2002-05-22 JP JP2002592931A patent/JP2004531570A/ja active Pending
- 2002-05-22 PL PL02367153A patent/PL367153A1/xx not_active Application Discontinuation
- 2002-05-22 RU RU2003134010/04A patent/RU2003134010A/ru not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/US2002/016529A patent/TNSN03119A1/en unknown
- 2003-11-20 IS IS7046A patent/IS7046A/is unknown
- 2003-11-21 NO NO20035183A patent/NO20035183D0/no not_active Application Discontinuation
- 2003-11-21 EC EC2003004860A patent/ECSP034860A/es unknown
- 2003-12-17 HR HR20031056A patent/HRP20031056A2/hr not_active Application Discontinuation
- 2003-12-22 BG BG108490A patent/BG108490A/bg unknown
-
2007
- 2007-05-17 US US11/749,840 patent/US20080107608A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040015716A (ko) | 2004-02-19 |
| IS7046A (is) | 2003-11-20 |
| BG108490A (bg) | 2005-01-31 |
| CA2448198A1 (en) | 2002-12-05 |
| US20030152520A1 (en) | 2003-08-14 |
| IL158958A0 (en) | 2004-05-12 |
| RU2003134010A (ru) | 2005-05-20 |
| HRP20031056A2 (en) | 2005-08-31 |
| NO20035183D0 (no) | 2003-11-21 |
| ECSP034860A (es) | 2004-01-28 |
| WO2002096421A1 (en) | 2002-12-05 |
| TNSN03119A1 (en) | 2005-12-23 |
| PL367153A1 (en) | 2005-02-21 |
| EP1392302A1 (en) | 2004-03-03 |
| US7223778B2 (en) | 2007-05-29 |
| US20080107608A1 (en) | 2008-05-08 |
| SK15432003A3 (sk) | 2004-05-04 |
| MXPA03010692A (es) | 2004-07-01 |
| AP2003002920A0 (en) | 2003-12-31 |
| BR0209920A (pt) | 2004-03-30 |
| JP2004531570A (ja) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400316A2 (hu) | CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0101204A2 (hu) | HIV-gátló pirimidinszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0301573A2 (hu) | Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0300350A2 (hu) | Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| NO20034523D0 (no) | Pyrazolderivater for behandling av HIV | |
| HUP0402313A2 (hu) | Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP0401740A2 (hu) | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0303841A2 (hu) | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk | |
| HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0300082A2 (en) | 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives, process for their preparation and use and pharmaceutical compositions containing them | |
| WO2005103003A3 (en) | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors | |
| HUP0400451A2 (hu) | Pirrolszármazékok és ezeket tartalmazó gyógyászati készítmények | |
| HUP0402309A2 (hu) | Glükokináz-aktivátorként szolgáló amidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| SE0102616D0 (sv) | Novel compounds | |
| HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DK1696905T3 (da) | Substituerede 2-aminotetraliner til forebyggende behandling af Morbus Parkinson | |
| ATE357228T1 (de) | Feste pharmazeutische formulierung enthaltend modafinil | |
| SE9904129D0 (sv) | Novel compounds | |
| CY1106973T1 (el) | Παραγωγα θειαζολινης ως εκλεκτικοι διαμορφωται υποδοχεως ανδρογονου (sarms) | |
| HUP0400179A2 (hu) | 2,5-Diaril-pirazin-származékok, 2,5-diaril-piridin-származékok és 2,5-diaril-pirimidin-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0500136A2 (hu) | Oxitocin antagonista hatású szubsztituált diketo-piperazinok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE501128T1 (de) | 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion | |
| HUP0401107A2 (hu) | Benzolgyűrűvel kondenzált új heterociklusos vegyületek és felhasználásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| TW200500097A (en) | Novel pharmaceutical formulations of modafinil | |
| HUP0301587A2 (hu) | Foszfodiészteráz V gátló hatású 5-amino-alkil-pirazolo[4,3-d]pirimidinek, ezeket tartalmazó gyógyszerkészítmények és eljárások az elżállításaikra |